Navigation Links
Oral Transmucosal Drug Delivery. Products, Players, Markets & Forecasts
Date:3/19/2013

DUBLIN, Ireland, March 19, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Oral Transmucosal Drug Delivery. Products, Players, Markets & Forecasts" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient discomfort when drugs are administered by the transmucosal route. We expect this market to experience healthy growth through 2015 as buccal technology is applied to existing drugs and as transmucosal formulations become an important route of administration for an increasing number of new NCEs. Growth in this sector will also be driven by the pressure to extend market protection for numerous existing drugs with soon-to-expire patents.

Highlights:

- Analyzes and evaluates oral transmucosal drug delivery technology platforms and their impact on the market

- Analyzes oral transmucosal drug products and pipeline product candidates

- Provides assessments of key oral transmucosal drug therapeutic categories

- Provides market data and forecasts to 2016

- Profiles mark
'/>"/>

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
2. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
3. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
4. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
5. BIOCRATES Life Sciences to Launch Waters Xevo® TQ MS Editions for Two of its Well-established Research Kit Products, AbsoluteIDQ® p180 and p150
6. Transdermal Hormone Replacement: Products, Players, Markets and Forecasts
7. Global Information Inc Offers Big Discounts on Market Forecasts for Surgical Sealants, Wound Closure Products, Spine Surgery Technology, and More
8. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
9. Transdermal Pain Management to 2016: Products, Markets, Forecasts and Opportunities
10. China Biologic Products, Inc. Adopts Stockholder Rights Plan
11. Wright Therapy Products, Inc. Closes $3 million Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources Group ... the EU5 countries ( France , ... Spain and the ... of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) ... uptake of Relvar as a first-line LABA/ICS FDC in ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Calif., Nov. 17 Poniard Pharmaceuticals, Inc. (Nasdaq: ... randomized, controlled Phase 2 trial of picoplatin in patients ... indicated that picoplatin, given once every four weeks in ... has comparable efficacy to oxaliplatin, given in combination with ...
... , LAKE ZURICH, Ill., Nov. 17 ... improving blood collection, separation, safety and availability, announced today ... the Verax Platelet PGD® test as a quality control ... platelets prior to transfusion. Fenwal is the exclusive ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 4
(Date:7/24/2014)... BUFFALO, N.Y. Primary care treatment of overweight and ... and child compared to when only the child is ... Pediatrics and conducted at the University at Buffalo ... in this study were overweight or obese and had ... was overweight or obese, according to body mass index ...
(Date:7/24/2014)... caffeine may worsen the hot flashes and night sweats ... through menopause, new survey data suggests. "While these ... intake may be useful for those postmenopausal women who ... Dr. Stephanie Faubion, director of the Women,s Health Clinic ... caffeine -- a stimulant found in coffee and colas ...
(Date:7/24/2014)... 24, 2014 A new study led by the ... interplay among bacteria, viruses and the immune system during ... their potential to infect others based on ... amounts of virus in their semen despite having low ... different levels of the virus can be found in ...
(Date:7/24/2014)... July 24, 2014 Memantine was initially developed ... marketed in Germany under the brand name Akatinol; it was ... as Ebixa and in the USA to Forest Labs as ... million in 2013. In the US, Forest reported Namenda sales ... expiry in Canada, Australia and the European region has increased ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Members of the ... Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, as ... appointed him to the Board and that his peers chose ... want to provide the best I can for the citizens ... am uniquely positioned to provide a special insight to concerns ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... contrast to normal cells, which only divide a finite number ... growth arrest or simply die, cancer cells never cease to ... have uncovered an important clue to one of the mechanisms ... April 22, 2011 issue of Molecular Cell , reveal ...
... -- A new poll finds that almost all parents of ... get exercise during each school day. However, one-third said their ... survey findings come at a time when U.S. schools continue ... Obesity is thought to affect one out of every six ...
... Monitoring Committee (DSMC) has determined that patients in a ... a standard chemotherapy regimen for advanced prostate cancer did ... patients on the same chemotherapy regimen who got a ... had advanced, hormone-refractory prostate cancer were given up to ...
... a high school athlete drops dead, the rare but ... For reasons that remain a mystery to scientists, some ... experience an unusual heart arrhythmia. With over-exertion, their hearts ... now, screening for the hard-to-detect syndrome has been prohibitively ...
... the worm is shedding light on a protein associated with ... a highly targeted way to treat them. University ... which is present in many cell types but whose exact ... protein controls key aspects of the movement, or secretion, of ...
... Even people who show a clear treatment ... like insomnia, sadness and decreased concentration, researchers at ... data from the largest study on the treatment ... working overall, missed these symptoms. If patients have ...
Cached Medicine News:Health News:A new ending to an old 'tail' 2Health News:A new ending to an old 'tail' 3Health News:U.S. Parents Want Kids More Active During School Day: Poll 2Health News:Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer 2Health News:Standing up for athletes at risk 2Health News:Worm studies shed light on human cancers 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 3
... The THERMOstar is a high performance temperature ... microplates. Temperature, shaking speed and incubation time ... the status parameters are displayed on the ... above and below the microplates provide uniform ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9 Broth...
An agent used for making solid microbiological media....
Medicine Products: